News | Molecular Imaging | May 28, 2020

PETNET Solutions and Zionexa USA Announce FDA Approval of Cerianna

New radiopharmaceutical intended for PET imaging of metastatic breast cancer patients

New radiopharmaceutical intended for PET imaging of metastatic breast cancer patients

May 27, 2020 — PETNET Solutions, Inc., a Siemens Healthineers company, and Zionexa USA, a wholly owned subsidiary of Zionexa SAS, have announced that the Food and Drug Administration (FDA) has approved Cerianna (fluoroestradiol F 18) injection for intravenous use. Cerianna (fluoroestradiol F 18) is a molecular imaging agent indicated for use in positron emission tomography (PET) imaging for the detection of estrogen receptor-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer. Cerianna (fluoroestradiol F 18) is the first FDA-approved F-18 PET imaging agent specifically indicated for use in patients with recurrent or metastatic breast cancer.

Cerianna (fluoroestradiol F 18) will be commercially available beginning in late 2020/early 2021 through PETNET Solutions, Inc., Zionexa USA’s manufacturer and exclusive commercial distributor in the U.S. Additional manufacturing sites will be added as each site receives regulatory approval to commence manufacturing.  

“PETNET Solutions, Inc., is proud to work with Zionexa USA as the exclusive U.S. commercial supplier making Cerianna (fluoroestradiol F 18) accessible to imaging centers and their breast cancer patients,” said Barry Scott, head of PETNET Solutions, Inc. “Our extensive network of radiopharmacies enables us to increase access to cutting-edge radiotracers such as Cerianna (fluoroestradiol F 18), helping healthcare facilities address the challenge of recurrent and metastatic breast cancer.”

“Zionexa is pleased to be able to make Cerianna (fluoroestradiol F 18) commercially available through the extensive manufacturing network of PETNET Solutions, Inc.,” said Peter Webner, chief executive officer of Zionexa USA. “PETNET has been a great partner to Zionexa and has surpassed our expectations as a contract manufacturer. Cerianna (fluoroestradiol F 18) will provide clinicians with additional, previously unavailable data on the estrogen receptor status of tumors across the patient’s entire body, providing additional data to enhance therapeutic decision-making.”

For more information: www.zionexa.com/

Related Content

Important milestone demonstrates the unrivalled experience, technological innovation and global market leadership of IBA and its clinical partners
News | Proton Therapy | September 25, 2020
September 25, 2020 — IBA (Ion Beam Applications SA) announced that more than 100,000 patients have now been treated w
Philips Azurion Lung Edition supports high precision diagnosis and minimally invasive therapy in one room
News | Lung Imaging | September 21, 2020
September 21, 2020 — Philips introduced...
Final rule includes mandatory participation for nearly 1,000 practices and does not allow sufficient time for transition

Getty Images

News | Radiation Oncology | September 21, 2020
September 21, 2020 — In response to the September 18 ...
According to a new report published by P&S Intelligence, the global radiotherapy market is expected to expand from $7.2M in 2019 to $17M by 2030.

Image courtesy of Accuray

Feature | Radiation Therapy | September 21, 2020 | By Melinda Taschetta-Millane
According to a...
Breast cancer patients whose disease has spread to their brains fare better if their metastases are picked up before they begin to cause symptoms, according to a study presented at the 12th European Breast Cancer Conference.

Getty Images

News | Breast Imaging | September 21, 2020
September 21, 2020 — Breast cancer patients whose disease has spread to their brains fare better if their metastases
Data from latest research presented at the ESMO Virtual Congress 2020 suggests COVID-19 pandemic halts cancer care and damages oncologists' wellbeing

Getty Images

News | Coronavirus (COVID-19) | September 17, 2020
September 17, 2020 — Delays and cancellation of cancer treatments and other safety measures undertaken to minimize th
Varian Drives Next Evolution of Proton Treatment Planning with Eclipse v16.1
News | Treatment Planning | September 15, 2020
September 15, 2020 — Varian announced it has received FDA 510(k) clearance for its Eclipse v16.1 treatment planning s
HABLE study prioritizes brain imaging and biomarker research among Mexican Americans.

Getty Images

News | PET Imaging | September 14, 2020
September 14, 2020 — To meet the pressing need to better understand the prevalence, progression, and clinical impact